These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 25103891)

  • 1. Storage and secretion of naturally occurring von Willebrand factor A domain variants.
    Groeneveld DJ; Wang JW; Mourik MJ; Dirven RJ; Valentijn KM; Voorberg J; Reitsma PH; Eikenboom J
    Br J Haematol; 2014 Nov; 167(4):529-40. PubMed ID: 25103891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Von Willebrand disease and Weibel-Palade bodies.
    Wang JW; Eikenboom J
    Hamostaseologie; 2010 Aug; 30(3):150-5. PubMed ID: 20680229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biogenesis of Weibel-Palade bodies in von Willebrand's disease variants with impaired von Willebrand factor intrachain or interchain disulfide bond formation.
    Wang JW; Groeneveld DJ; Cosemans G; Dirven RJ; Valentijn KM; Voorberg J; Reitsma PH; Eikenboom J
    Haematologica; 2012 Jun; 97(6):859-66. PubMed ID: 22207689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracellular storage and regulated secretion of von Willebrand factor in quantitative von Willebrand disease.
    Wang JW; Valentijn KM; de Boer HC; Dirven RJ; van Zonneveld AJ; Koster AJ; Voorberg J; Reitsma PH; Eikenboom J
    J Biol Chem; 2011 Jul; 286(27):24180-8. PubMed ID: 21596755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. von Willebrand factor propeptide missense variants affect anterograde transport to Golgi resulting in ER retention.
    Yadegari H; Biswas A; Ahmed S; Naz A; Oldenburg J
    Hum Mutat; 2021 Jun; 42(6):731-744. PubMed ID: 33942438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced von Willebrand factor secretion is associated with loss of Weibel-Palade body formation.
    Castaman G; Giacomelli SH; Jacobi PM; Obser T; Budde U; Rodeghiero F; Schneppenheim R; Haberichter SL
    J Thromb Haemost; 2012 May; 10(5):951-8. PubMed ID: 22429825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re-establishment of VWF-dependent Weibel-Palade bodies in VWD endothelial cells.
    Haberichter SL; Merricks EP; Fahs SA; Christopherson PA; Nichols TC; Montgomery RR
    Blood; 2005 Jan; 105(1):145-52. PubMed ID: 15331450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of cysteine 584 impairs the storage and release, but not the synthesis of von Willebrand factor.
    Daidone V; Barbon G; Pontara E; Cattini GM; Gallinaro L; Zampese E; Pizzo P; Casonato A
    Thromb Haemost; 2014 Dec; 112(6):1159-66. PubMed ID: 25230768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of intracellular storage and regulated secretion of 3 von Willebrand disease-causing variants of von Willebrand factor.
    Michaux G; Hewlett LJ; Messenger SL; Goodeve AC; Peake IR; Daly ME; Cutler DF
    Blood; 2003 Oct; 102(7):2452-8. PubMed ID: 12791651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dominant p.Thr274Pro mutation in the von Willebrand factor propeptide causes the von Willebrand disease type 1 phenotype in two unrelated patients.
    Pagliari MT; Baronciani L; Cordiglieri C; Colpani P; Cozzi G; Siboni SM; Peyvandi F
    Haemophilia; 2022 Mar; 28(2):292-300. PubMed ID: 35064738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dispatch and delivery at the ER-Golgi interface: how endothelial cells tune their hemostatic response.
    Kat M; Margadant C; Voorberg J; Bierings R
    FEBS J; 2022 Nov; 289(22):6863-6870. PubMed ID: 35246944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
    Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
    Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homozygous type 2N R854W von Willebrand factor is poorly secreted and causes a severe von Willebrand disease phenotype.
    Castaman G; Giacomelli SH; Jacobi P; Obser T; Budde U; Rodeghiero F; Haberichter SL; Schneppenheim R
    J Thromb Haemost; 2010 Sep; 8(9):2011-6. PubMed ID: 20586924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the storage and secretion of von Willebrand factor in blood outgrowth endothelial cells derived from patients with von Willebrand disease.
    Wang JW; Bouwens EA; Pintao MC; Voorberg J; Safdar H; Valentijn KM; de Boer HC; Mertens K; Reitsma PH; Eikenboom J
    Blood; 2013 Apr; 121(14):2762-72. PubMed ID: 23426949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weibel-Palade bodies: a window to von Willebrand disease.
    Valentijn KM; Eikenboom J
    J Thromb Haemost; 2013 Apr; 11(4):581-92. PubMed ID: 23398618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
    Michiels JJ; Gadisseur A; Budde U; Berneman Z; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. von Willebrand factor propeptide variants lead to impaired storage and ER retention in patient-derived endothelial colony-forming cells.
    Bowman M; Casey L; Selvam SN; Lima PDA; Rawley O; Hinds M; Tuttle A; Grabell J; Iorio A; Walker I; Lillicrap D; James P
    J Thromb Haemost; 2022 Jul; 20(7):1599-1609. PubMed ID: 35466528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.